Results 51 to 60 of about 19,753 (208)

Codelivery of zoledronic acid and double-stranded RNA from core-shell nanoparticles

International Journal of Nanomedicine, 2013
Li Chen,1 Yunfei Ding,2 Yongzhong Wang,3 Xingrong Liu,2 RJ Babu,1 WR Ravis,1 Weili Yan21Department of Pharmaceutical Sciences, Harrison School of Pharmacy, Auburn University, Auburn, AL, USA; 2Department of Pharmaceutical Sciences, College of Life ...
Yan W, Ravis WR, Babu RJ, Liu X, Wang Y, Ding Y, Chen L   +6 more
doaj  

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

Denosumab versus zoledronic acid in cases of surgically unsalvageable giant cell tumor of bone: A randomized clinical trial

Journal of Bone Oncology, 2019
Background: Although denosumab has been approved as an antiresorptive agent for giant cell tumor of bone, its efficacy has not been proven. Objectives: To compare the efficacy and safety of denosumab and zoledronic acid treatment in patients with ...
Shenglong Li, Peng Chen, Qiankun Yang
doaj   +1 more source

OUR EXPERIENCE WITH ZOLEDRONIC ACID IN THE TREATMENT OF PATIENTS WITH NON- SMALL CELL LUNG CANCER AND BONE METASTASES [PDF]

Journal of IMAB, 2013
Objective: Bone metastases occur in 30- 40% of patients with lung cancer. The aim of this study was to assess the efficacy and safety of Zoledronic acid, a third generation biphosphonates, in patients with non- small cell lung cancer and bone metastases.
Deyan N. Davidov
doaj   +1 more source

Recommendations for bone‐directed therapy in patients with neuroendocrine tumour skeletal metastases at the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting

Internal Medicine Journal, EarlyView.
Abstract The role of anti‐resorptive agents in patients with bone metastases from neuroendocrine neoplasms is unclear. Our aim was to review bone‐specific treatment recommendations by the New Zealand National Neuroendocrine Tumour Multidisciplinary Meeting (MDM).
Gayle Radley, Marianne S Elston, Ben Lawrence, Veronica Boyle   +3 more
wiley   +1 more source

Prenylation inhibition-induced cell death in melanoma: reduced sensitivity in BRAF mutant/PTEN wild-type melanoma cells.

PLoS ONE, 2015
While targeted therapy brought a new era in the treatment of BRAF mutant melanoma, therapeutic options for non-BRAF mutant cases are still limited. In order to explore the antitumor activity of prenylation inhibition we investigated the response to ...
Tamás Garay, István Kenessey, Eszter Molnár, Éva Juhász, Andrea Réti, Viktória László, Anita Rózsás, Judit Dobos, Balázs Döme, Walter Berger, Walter Klepetko, József Tóvári, József Tímár, Balázs Hegedűs   +13 more
doaj   +1 more source

Radiographic Analysis of MRONJ in Osteoporotic and Oncologic Patients on Bisphosphonates or Denosumab

Oral Diseases, EarlyView.
ABSTRACT Introduction Medication‐Related Osteonecrosis of the Jaw (MRONJ) is a severe adverse effect of antiresorptive and antiangiogenic treatment, primarily in osteoporotic and oncologic patients. The disease is characterized by persistent jawbone necrosis that results in significant impairment of the quality of life of involved patients.
Omar Ghanaiem, Gavriel Chaushu, Daya Masri   +2 more
wiley   +1 more source

Effect of metformin on inflammation and bone damage in a rat model of medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 134, Issue 1, February 2026.
Abstract This study investigated how chronic metformin administration modulates the cellular profile and inflammatory markers in a zoledronic acid‐based rat model of medication‐related osteonecrosis of the jaw (MRONJ). Male Wistar rats were allocated to different treatments: (i) naïve, (ii) MRONJ (zoledronic acid, 0.2 mg/kg, i.v.
Liviane Maria Alves Rabelo, Mariana Vasconcelos Guimarães, Aurilene Gomes Cajado, José Vitor Mota Lemos, Felipe Domingos de Sousa, Nylane Maria Nunes Alencar, Vilma de Lima, Paulo Goberlânio de Barros Silva, Ana Paula Negreiros Nunes Alves, Deysi Viviana Tenazoa Wong, Roberto César Pereira Lima‐Júnior   +10 more
wiley   +1 more source

Navigating the evolving management of smoldering multiple myeloma

HemaSphere, Volume 10, Issue 1, January 2026.
Abstract Smoldering multiple myeloma (SMM) represents an intermediate clinical stage between monoclonal gammopathy of undetermined significance (MGUS) and symptomatic multiple myeloma (MM). SMM carries a highly variable risk of progression to MM, requiring individualized risk stratification to guide management.
M. Bakri Hammami, Rafael R. Canevarolo, Ariosto S. Silva, Melissa Alsina, Nagi Kumar, Rachid Baz, Kenneth H. Shain   +6 more
wiley   +1 more source

Zoledronic Acid-Loaded β-TCP Inhibits Tumor Proliferation and Osteoclast Activation: Development of a Functional Bone Substitute for an Efficient Osteosarcoma Treatment [PDF]

, 2021
Yuka Kameda, Mamoru Aizawa, Taira Sato, Michiyo Honda   +3 more
openalex   +1 more source